



Anaptys Announces Participation at Upcoming Investor Conferences

February 5, 2026

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

Guggenheim Emerging Outlook: Biotech Summit 2026, New York, NY

- Format – Fireside chat and 1x1 investor meetings
- Date and Time – Wednesday, Feb. 11, 2026 at 3:00pm ET

Piper Sandler Virtual Novel Targets in Immunology Symposium, Virtual

- Format – Fireside chat
- Date and Time – Thursday, Feb. 12, 2026 at 12:30pm ET

TD Cowen 46th Annual Health Care Conference, Boston, MA

- Format – Fireside chat and 1x1 investor meetings
- Date and Time – Wednesday, Mar. 4, 2026 at 11:50am ET

Barclays 28th Annual Global Healthcare Conference, Miami, FL

- Format – Fireside chat and 1x1 investor meetings
- Date and Time – Tuesday, Mar. 10, 2026 at 8:30am ET

UBS Biotech Summit Miami: Catalyst for Change, Miami, FL

- Format – 1x1 investor meetings
- Date and Time – Tuesday, Mar. 10, 2026

Leerink Global Healthcare Conference, Miami FL

- Format – Fireside chat and 1x1 investor meetings
- Date and Time – Wednesday, Mar. 11, 2026 at 2:20pm ET

Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at <https://ir.anaptysbio.com/presentations-and-events>. Replays of the webcasts will be available for at least 30 days following the events.

About Anaptys

Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company's pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease and eosinophilic esophagitis; and ANB101, a BDCA2 modulator, in a Phase 1a trial. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (*Jemperli* (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on [LinkedIn](#).

Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more [here](#).

Contact:

Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com



Source: AnaptysBio, Inc.